Vaxart Stock

Vaxart FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vaxart (VXRT) as of Aug 13, 2026 is 46.36 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.69 % — a change of -31.51% (lower).

FCF Conversion

46.36 %

YoY

-31.51%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vaxart is 2026 46.36 % . FCF Conversion Rate (FCF/EBITDA) of Vaxart was 2025 67.69 % . It decreases by -31.51% lower compared to the previous year.
Access this data via the Eulerpool API

Vaxart Stock analysis

What does Vaxart do? Vaxart Inc is a US biotechnology company that was founded in 2004 and is based in South San Francisco, California. The company specializes in the development of oral vaccines and therapeutics. Vaxart is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaxart stock

FCF Conversion Rate (FCF/EBITDA) of Vaxart is 46.36 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Vaxart changed from 67.69 % to 46.36 %, representing a -31.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vaxart since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vaxart with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Vaxart

All Key Metrics — Vaxart